Want to see ZNTL full AI Analyst Report?

Zentalis Pharmaceuticals (ZNTL) Price & Analysis

395 Followers

ZNTL Stock Chart & Stats

$1.41

-$0.17(-5.69%)

At close: Jan 08 4:00 PM EST

$1.41

-$0.17(-5.69%)

Day’s Range― - ―

52-Week Range$1.13 - $6.95

Previous CloseN/A

Volume750.15K

Average Volume (3M)716.92K

Market Cap

$345.25M

Enterprise Value$264.42M

Total Cash (Recent Filing)$211.76M

Total Debt (Recent Filing)$38.65M

Price to Earnings (P/E)―

Beta3.44

Next Earnings

Aug 12, 2026

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.73

Shares Outstanding71,186,350

10 Day Avg. Volume819,524

30 Day Avg. Volume716,917

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)0.45

Price to Sales (P/S)0.00

P/FCF Ratio-0.77

Enterprise Value/Market Cap0.77

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.75K

Enterprise Value/Ebitda-2.02

Forecast

1Y Price Target

$7.00

Price Target Upside396.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.94

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Late-stage Clinical Progression (Phase 3 ASPENOVA)Advancing azenosertib into a confirmatory, FDA-aligned Phase 3 materially raises the program's strategic value. A successful ASPENOVA outcome would enable full approval and commercialization, converting R&D investment into a durable revenue stream and de-risking the company’s lead asset over the medium term.

Encouraging Clinical Efficacy In Ovarian CancerRobust response rates and manageable safety in heavily pre-treated, platinum-resistant ovarian cancer indicate meaningful clinical activity. These durable efficacy signals support both monotherapy and taxane-combination strategies, expanding potential label use and commercial uptake if late-stage trials confirm benefits.

Funded Runway And Modest LeverageHaving cash to fund pivotal trials into late 2027 reduces near-term financing pressure and supports continuity of late-stage programs. Combined with modest reported leverage, this financial position gives the company flexibility to complete critical milestones that determine long-term commercial prospects.

Bears Say

No Current Product RevenueAs a development-stage biotech with zero trailing sales, Zentalis lacks recurring commercial revenues to fund operations. Persistent large net losses mean the company must rely on financing or partnerships to sustain development, making long-term viability contingent on regulatory and clinical success.

Sustained Negative Operating And Free Cash FlowDeeply negative operating and free cash flow implies ongoing dilution risk and financial vulnerability if trial timelines slip or costs rise. Even with burn improvement, sustained negative cash generation constrains strategic optionality and can force funding that dilutes existing shareholders.

Concentration Risk Around A Single Lead AssetThe company’s pipeline and strategic outlook are heavily dependent on azenosertib. This single-asset concentration means commercial and balance-sheet outcomes hinge on a single program's trial and regulatory results; failure or unfavorable data would materially impair long-term prospects.

Zentalis Pharmaceuticals News

Zentalis assumed with an Outperform at Oppenheimer

Oppenheimer assumed coverage of Zentalis (ZNTL) with an Outperform rating and $9 price target The company is entering...

17d ago

ZNTL

Zentalis Shareholders Back Directors, Auditors and Executive Pay

Zentalis Pharmaceuticals ( ($ZNTL) ) has shared an update. On June 16, 2026, Zentalis Pharmaceuticals, Inc. held its...

13d ago

ZNTL

Zentalis Pharmaceuticals Expands Board, Appoints New Director

The latest update is out from Zentalis Pharmaceuticals ( ($ZNTL) ). Effective May 22, 2026, Zentalis Pharmaceuticals expanded...

1M ago

ZNTL

Analyst Reiterates Buy on Zentalis as New MUIR Data Bolster Azenosertib Outlook; $10 Price Target Unchanged

In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Zentalis Pharmaceuticals,...

1M ago

ZNTL

Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer

Zentalis Pharmaceuticals ( ($ZNTL) ) has issued an announcement. On May 21, 2026, Zentalis Pharmaceuticals reported Phase 1b...

1M ago

ZNTL

Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts

Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Zentalis Pharmaceuticals and keeping the price...

2M ago

ZNTL

Zentalis reports Q1 EPS (50c), consensus (52c)

“This quarter, we built momentum with achievement of key milestones advancing azenosertib in our registration-intended Phase 2 and...

2M ago

ZNTL

Zentalis Advances Azenosertib with New Trial Updates

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an announcement. On May 12, 2026, Zentalis Pharmaceuticals reported first-quarter 2026...

2M ago

ZNTL

ZNTL Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Zentalis Pharmaceuticals Inc (ZNTL) is scheduled to report 1st quarter earnings on 05/13/2026. Regarding Q1 estimates, Wall Street...

2M ago

ZNTL

Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an update. On May 5, 2026, Zentalis Pharmaceuticals announced that the...

2M ago

ZNTL

Zentalis Highlights New Azenosertib Data in Breast Cancer

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an update. On April 17, 2026, at the American Association for...

3M ago

ZNTL

Zentalis to present azenosertib preclinical data in TNBC at AACR meeting

Zentalis (ZNTL) announced data from two posters being presented at the 2026 American Association for Cancer Research Annual...

3M ago

ZNTL

Midday Fly By: CoreWeave inks Anthropic, TSMC reports March sales bump

The major averages were mixed near noon, with the Dow Jones Industrial Average in the red, the Nasdaq...

3M ago

Zentalis price target raised to $10 from $6 at Guggenheim

Guggenheim raised the firm’s price target on Zentalis (ZNTL) to $10 from $6 and keeps a Buy rating...

3M ago

ZNTL

ZNTL FAQ

What was Zentalis Pharmaceuticals’s price range in the past 12 months?

Zentalis Pharmaceuticals lowest stock price was $1.13 and its highest was $6.95 in the past 12 months.

What is Zentalis Pharmaceuticals’s market cap?

Zentalis Pharmaceuticals’s market cap is $345.25M.

When is Zentalis Pharmaceuticals’s upcoming earnings report date?

Zentalis Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.

How were Zentalis Pharmaceuticals’s earnings last quarter?

Zentalis Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.023.

Is Zentalis Pharmaceuticals overvalued?

According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zentalis Pharmaceuticals pay dividends?

Zentalis Pharmaceuticals does not currently pay dividends.

What is Zentalis Pharmaceuticals’s EPS estimate?

Zentalis Pharmaceuticals’s EPS estimate is -0.48.

How many shares outstanding does Zentalis Pharmaceuticals have?

Zentalis Pharmaceuticals has 71,186,350 shares outstanding.

What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?

Zentalis Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?

Currently, no hedge funds are holding shares in ZNTL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Zentalis Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-53.61%

Trailing 12-Months

Asset Growth

-34.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals (ZNTL) Earnings & Revenues

Historic Earnings Reports

ZNTL Stock 12 Month Forecast

Average Price Target

$7.00

▲(396.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.85,5.246153846153846,5.642307692307692,6.038461538461538,6.434615384615384,6.8307692307692305,7.226923076923077,7.623076923076923,8.01923076923077,8.415384615384616,8.811538461538461,9.207692307692309,9.603846153846154,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.85,5.015384615384615,5.18076923076923,5.346153846153846,5.5115384615384615,5.676923076923076,5.842307692307692,6.007692307692308,6.173076923076923,6.338461538461538,6.503846153846154,6.669230769230769,6.834615384615384,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.85,4.7846153846153845,4.719230769230769,4.653846153846153,4.588461538461538,4.523076923076923,4.457692307692308,4.392307692307692,4.326923076923077,4.2615384615384615,4.196153846153846,4.13076923076923,4.065384615384615,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.57,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >